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Summary
Background: The epidermal growth factor (EGF) stimulates
rapid tyrosine phosphorylation of the EGF receptor (EGFR).
This event precedes signaling from both the plasma
membrane and from endosomes, and it is essential for recruit-
ment of a ubiquitin ligase, CBL, that sorts activated receptors
to endosomes and degradation. Because hyperphosphoryla-
tion of EGFR is involved in oncogenic pathways, we performed
an unbiased screen of small interfering RNA (siRNA) oligonu-
cleotides targeting all human tyrosine phosphatases.
Results: We report the identification of PTPRK and PTPRJ
(density-enhanced phosphatase-1 [DEP-1]) as EGFR-targeting
phosphatases. DEP-1 is a tumor suppressor that dephosphor-
ylates and thereby stabilizes EGFR by hampering its ability
to associate with the CBL-GRB2 ubiquitin ligase complex.
DEP-1 silencing enhanced tyrosine phosphorylation of endo-
somal EGFRs and, accordingly, increased cell proliferation. In
line with functional interactions, EGFR and DEP-1 form phys-
ical associations, and EGFR phosphorylates a substrate-trap-
ping mutant of DEP-1. Interestingly, the interactions of DEP-1
and EGFR are followed by physical segregation: whereas
EGFR undergoes endocytosis, DEP-1 remains confined to
the cell surface.
Conclusions: EGFR and DEP-1 physically interact at the cell
surface and maintain bidirectional enzyme-substrate interac-
tions, which are relevant to their respective oncogenic and
tumor-suppressive functions. These observations highlight the
emerging roles of vesicular trafficking in malignant processes.
Introduction
The balanced action of protein tyrosine kinases (PTKs) and
protein tyrosine phosphatases (PTPs) is considered a major
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Toronto, ON M5G 1X8, Canadaswitch of many signal transduction pathways [1]. Interestingly,
both families include transmembrane receptor-like enzymes,
namely receptor tyrosine kinases (RTKs) and the less under-
stood receptor-like PTPs (RPTPs). This divergence is exempli-
fied by the epidermal growth factor receptor (EGFR) [2].
Upon EGF binding and subsequent structural alterations,
receptor dimers are stabilized, thereby allowing activation of
the intrinsic kinase domain and self-phosphorylation. Con-
comitant with transfer of active receptors from the plasma
membranes to endosomes, phosphorylated tyrosine residues
of EGFR act as docking sites for adaptors and enzymes that
activate either stimulatory pathways, such as the mitogen-
activated protein kinase (MAPK), or inhibitory cascades,
like the CBL ubiquitin ligase. By ubiquitylating EGFR, CBL
instigates a process mediated by four endosomal sorting
complexes (ESCRTs), culminating in lysosomal degradation
of EGFR [3].
Several PTPs have been identified as candidate regula-
tors of EGFR. For instance, EGFR phosphorylation was
reduced upon inducible expression of RPTP-sigma [4]. Other
examples include PTPN1/PTP1B [5, 6] and PTPN2/TCPTP
[7]. Notably, PTP1B-mediated dephosphorylation of EGFR
requires receptor endocytosis [8]. On the other hand, TCPTP
is activated at the plasma membrane by a collagen-binding
integrin to negatively regulate EGFR [9]. Finally, forced coex-
pression of EGFR and various RPTPs enabled identification
of RPTP-kappa as an enzyme capable of reducing EGFR
phosphorylation [10].
The present study employed a small interfering RNA (siRNA)
library representing all human PTPs to identify PTPs able
to catalytically interact with EGFR. The screen identified a
candidate EGFR-targeting RPTP, namely DEP-1 (density-
enhanced phosphatase-1, also designated CD148, PTP-eta,
and PTPRJ). Consistent with the induction of DEP-1 expres-
sion in contact-inhibited cells [11], the corresponding gene is
often deleted or mutated in carcinomas [12], and DEP-1
exhibits tumor-suppressor activity when ectopically overex-
pressed [13–16]. Several previous studies identified RTK
substrates of DEP-1, including the vascular endothelial growth
factor (VEGF) receptor [17–19]. Beyond the unbiased identifi-
cation of EGFR as a substrate for DEP-1, the results we
present shed light on the molecular details of RTK-RPTP inter-
actions: EGFR-DEP complexes exist at the cell surface prior to
ligand binding. On binding of EGF, DEP-1 dephosphorylates
and thereby stabilizes EGFR and inhibits signaling. Eventually,
EGFR undertakes a route leading to endosomes and lyso-
somes, but DEP-1 remains at the cell surface. The implications
of this segregation are discussed in the context of compart-
mentalized EGFR signaling and the diverse involvement of
derailed endocytosis in cancer [20].
Results
An Unbiased Screen Identifies DEP-1 as a Suppressor
of EGFR Signaling and Degradation
To substantiate the role of PTPs in EGF-induced phosphoryla-
tion events, we treated HeLa cells with two different phospha-
tase inhibitors and then stimulated them with EGF (Figure 1A).
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1789A mixture of H2O2 and sodium orthovanadate (HV), which
potently but nonspecifically inhibits PTPs [21], caused a signif-
icant increase in both basal and EGF-induced receptor phos-
phorylation (Figure 1A). The vitamin K derivative compound
5, a mild inhibitor of PTPs [22], exerted similar but weaker
effects (Figure 1A), implying that PTPs critically regulate both
basal and EGF-driven receptor phosphorylation.
To identify PTPs that underlie dephosphorylation of EGFR,
we screened all human PTPs with a library of siRNA oligonu-
cleotides, collectively targeting 38 PTPs. Pools of four oligonu-
cleotides were transfected into cells, and 48 hr later the cells
were stimulated with EGF (see flow diagram in Figure S1 avail-
able online). Thereafter, whole-cell lysates were separately
immunoblotted with antibodies to EGFR, antibodies to phos-
photyrosine (pY99), and antibodies to the active form of
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Figure 1. An Unbiased Genetic Screen Identifies Protein Tyrosine Phospha-
tases Regulating EGF-Mediated Receptor Phosphorylation and Degrada-
tion
(A) HeLa cells were serum starved for 16 hr; treated with either a mixture of
H2O2 (0.2 mM) and sodium orthovanadate (1 mM for 15 min; HV), compound
5 (Cpd5; 20 mM for 30 min), or ethanol (control; 30 min); and then stimulated
with EGF (20 ng/ml) for the indicated time intervals. Whole-cell lysates were
blotted with the indicated antibodies.
(B and C) Mixtures of siRNA oligonucleotides were transfected into HeLa
cells, which were then incubated for 32 hr and serum starved for 16 hr.
The cells were then stimulated with EGF (20 ng/ml) for the indicated intervals
and were lysed. Whole cell lysates were blotted with the indicated anti-
bodies, including an anti-phosphotyrosine antibody (pY99) and antibodies
to the active (pERK) and general (gERK) forms of ERK.
(D) HeLa cells were transiently transfected with DEP-1 siRNA oligonucleo-
tides or with control siRNA (each at 10 nM), incubated for 32 hr, serum
starved for 16 hr, and stimulated with EGF (20 ng/ml) for the indicated
time intervals. Whole-cell lysates were immunoblotted with the indicated
antibodies.
(E) HeLa cells were treated and processed as in (D). EGFR phosphorylation
was quantified via densitometric analysis and normalized to total EGFR
level. One representative experiment (n = 3) is shown.ERK1/2. The library was independently screened twice, and
candidates displaying undetectable messenger RNA (mRNA)
levels in HeLa cells (Table S1) were eliminated. The screens
repeatedly identified PTPRK and DEP-1 (see examples in
Figures 1B and 1C). Notably, PTPRK has previously been
identified on the basis of coexpressing PTPs together with
EGFR in receptor null cells [10], whereas the DEP-1 ortholog
of C. elegans negatively regulates the worm’s EGFR [23].
To validate the knockdown effect of the pool of four siRNA
oligonucleotides, collectively targeting DEP-1, we tested indi-
vidual components, each targeting a distinct part of the DEP-1
transcript. This experiment confirmed that all four independent
siRNAs were able to reduce expression of DEP-1 (Figure S2).
Next, we transfected HeLa cells with the pool of siRNA oligo-
nucleotides and stimulated them with EGF (Figure 1D). This
experiment demonstrated effective siRNA-mediated inhibition
of DEP-1 expression and a concomitant enhancement of
receptor phosphorylation (peaking at 15 min; Figure 1E). In
addition, DEP-1 knockdown accelerated EGFR degradation,
and this effect was evident as early as 5 min after EGF stimu-
lation (Figure 1D). By employing commercially available anti-
bodies, which are supposed to recognize specific tyrosine
phosphorylation sites of EGFR, we found that depletion of
endogenous DEP-1 nonselectively increased receptor phos-
phorylation, affecting all three sites we analyzed (tyrosines
1045, 1068, and 1173; data not shown). Finally, consistent
with enhanced phosphorylation and accelerated degradation
of EGFR, we observed in DEP-1-depleted HeLa cells an
increase in EGF-stimulated ERK1/2 activation and an earlier
decay relative to control cells (Figure 1D).
Knockdown of DEP-1 Enhances Receptor Phosphorylation
in Endosomes
To extend the functional analyses of EGFR-DEP-1 interactions
to a cellular outcome, we referred to glioblastoma multiforme
(GBM), an aggressive brain tumor often presenting overactive
EGFRs. As a first step, we screened several GBM cell lines and
identified Ln229 cells as high expressors of DEP-1 (Figure 2A).
Next, we used siRNA-DEP-1 to achieve effective knockdown.
Most importantly, we found that knockdown of DEP-1 resulted
in remarkable enhancement of EGFR phosphorylation (Fig-
ure 2B), and this was associated with increased cell prolifera-
tion (Figure 2C; p = 0.001). These results confirmed that
mammalian DEP-1, similar to the invertebrate version, nega-
tively regulates EGFR signaling, which prompted us to analyze
the underlying mechanisms.
Our next set of experiments employed siRNA-treated HeLa
cells, immunofluorescence, and antibodies specific to EGFR
or to phosphorylated tyrosine 1173 (pY1173). As expected,
following stimulation with EGF (10 min), the receptor redistrib-
uted to endosomes (Figure 2D). Image analyses revealed that
the intensity of endosomal pY1173 was elevated in the majority
(67%) of siDEP-1-treated cells, as compared to siControl cells
(16%; Figures 2D and 2E). Hence, we compared the vesicular
pY1173 signal (n w 50; >25 cells) in control and DEP-1-
depleted cells (Figure 2E). This analysis confirmed that the
fraction of pY1173-enriched endosomes was significantly
higher in DEP-1-knockdown cells, as compared to control
cells (p < 0.001; t test).
In conclusion, depletion of endogenous DEP-1 indicated
that the phosphatase normally restricts tyrosine phosphoryla-
tion of EGFR, thereby curtailing signaling as well as cellular
proliferation and preventing transfer of active receptors to
endosomes. This latter observation is consistent with
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transfer from the plasma membrane to endosomes [24].
DEP-1 Gain of Function Decreases Signaling Downstream
to EGFR and Inhibits Ligand-Induced Receptor
Degradation
We next employed ectopic expression of DEP-1 to examine
possible reciprocal effects to those reflected by siRNA-
treated cells. Forty-eight hours following transfection with
a plasmid encoding wild-type (WT), HA (hemagglutinin epi-
tope)-tagged DEP-1, HeLa cells were stimulated with EGF
and whole-cell extracts were analyzed (Figures 3A and 3B).
DEP-1 overexpression reduced ligand-induced phosphoryla-
tion as well as retarded receptor degradation. For example,
by 60 min of stimulation, only a small fraction of EGFR
escaped degradation; ectopic DEP-1 not only increased this
fraction but almost completely erased its tyrosine phosphory-
lation (Figure 3B). Additionally, the decrease in EGFR activa-
tion was followed by decreased activation of ERK1/2 (Figures
3A and 3C). Moreover, the effect of DEP-1 on MAPK activation
was reflected in reduced transcription of the FOS gene
(Figure 3C).
To corroborate a model of DEP-1-enabling escape from
degradation, we applied immunofluorescence and WT or
a catalytically inactive mutant of DEP-1-HA (C1239S, denoted
Figure 2. Knockdown of DEP-1 Increases Phosphorylation
of Vesicular EGFRs and Enhances Proliferation of Glioblas-
toma Cells
(A) Whole extracts of Ln229 and T98 glioblastoma cells were
immunoblotted with antibodies to DEP-1 or the p85 subunit
of phosphoinositide 3-kinase.
(B) Ln229 cells were transfected with siRNA oligonucleotides
targeting DEP-1 transcripts. Following 48 hr of incubation,
cells were harvested for immunoblotting analysis.
(C) Ln229 cells were transfected with siRNA oligonucleotides
targeting DEP-1 transcripts, then incubated for 48 hr and
plated in 96-well plates under 1% serum. Proliferation was
measured after 3 days and compared to day 1. *p = 0.001.
(Da–Df) HeLa cells were transfected with DEP-1-siRNA
(10 nM; Dd–Df) or with control siRNA (Da–Dc) and then stim-
ulated with EGF (20 ng/ml, 10 min). Thereafter, cells were
analyzed by immunofluorescence with an antibody to
EGFR or to phosphorylated EGFR (pY1173). Images were
taken at the same exposure time. Arrowheads indicate vesi-
cles positive for both EGFR and pY1173; arrows mark EGFR-
positive but pY1173-negative vesicles. Enlarged areas show
internalized EGFR in vesicles. Scale bar represents 10 mm.
(E) Left: the number of cells displaying >10 pY1173-positive
vesicles are compared in DEP-1-siRNA- and control-treated
HeLa cells. Data are expressed as mean 6 standard devia-
tion (SD) (bars) of three independent measurements. Right:
fluorescence intensities of pY1173-positive vesicles (nw 50;
5 cells) were analyzed with NIH ImageJ software. The experi-
ment was repeated twice.
CS). Cells were either unstimulated or stimulated
with EGF for 10 min, then stained with an anti-
body to HA or to phosphorylated tyrosine 1173
of EGFR (pY1173; Figure 3D). Ectopic WT-DEP-1
localized to the plasma membrane as well as to
polar perinuclear sites, which may correspond
to biosynthetic compartments. Unlike unstimu-
lated cells, which displayed very weak pY1173
fluorescence signal (Figures 3Db and 3De),
EGF stimulation remarkably increased pY1173
(compare Figures 3Db and 3Dh). Moreover, whereas the
pY1173 signal of untransfected cells largely corresponded
to endosomes containing the endogenous EGFR of HeLa
cells, 95% of WT-DEP-1-expressing cells displayed no (or
very weak) punctate pY1173 staining (Figures 3D and 3E).
In sharp contrast to WT-DEP-1, vesicular pY1173-EGFR
was detectable in most cells expressing the mutant form of
the phosphatase (Figures 3Dj–3Dl and 3E). Only in a small
fraction of CS-DEP-1-expressing cells did we observe a
reduction in vesicular pY1173 (Figure 3E), suggesting that
DEP-1 strongly inhibits removal of active EGFR molecules
from the cell surface into endosomes. In conclusion, the
results shown in Figure 3 indicate that DEP-1 can dephos-
phorylate EGFR at the cell surface; this phosphatase activity
is responsible for blocking endocytosis of active receptors
and for stabilizing a dephosphorylated form of EGFR at the
plasma membrane.
EGFR and DEP-1 Colocalize and Maintain Bidirectional
Interactions
The ability of DEP-1 to dephosphorylate EGFR molecules
predicted physical interactions that are confined to the cell
surface. To test this model, we constructed a mutant of DEP-1
whose conserved aspartate 1205 had been replaced by an
alanine (DA mutant), an approach developed for PTP1B [5].
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Figure 3. Ectopic DEP-1 Decreases Receptor Phosphorylation, Stabilizes EGFR, and Inhibits Downstream Signaling
(A) HeLa cells were transfected with a plasmid encoding HA (hemagglutinin epitope)-tagged DEP-1 or with a control expression vector and then incubated for
32 hr, serum starved for 16 hr, and stimulated with EGF (20 ng/ml) for the indicated time intervals. Thereafter, cell extracts were analyzed by immunoblotting.
(B) HeLa cells were treated as in (A). EGFR phosphorylation was quantified and normalized. One representative experiment (n = 3) is shown.
(C) HeLa cells were treated as in (A) and stimulated with EGF (20 ng/ml) for the indicated intervals. Left: cells were processed for immunoblotting and densi-
tometry of pERK1/2 levels (normalized to total ERK2 level; gERK). Right: cells were lysed and total RNA was prepared and used for reverse transcription. Real-
time PCR was carried out with c-FOS primers.
(Da–Dl)HeLacellswere transfectedwithplasmidsencodingwild-typeHA-DEP-1 (Da–DcandDg–Di)oracatalytically inactivemutant (CS;Dd–DfandDj–Dl)andthen
incubated for 32 hr, serum starved for 16 hr (Da–Df), and stimulated with EGF (20 ng/ml) for 10 min (Dg–Dl). Cells were then fixed and analyzed by immunofluores-
cencewith an antibodyto HA (Da, Dd, Dg,and Dj)or tophosphorylatedEGFR(pY1173; Db, De, Dh, and Dk). ImagesofphosphorylatedEGFRwere takenat thesame
exposure time.Endogenousphosphorylated EGFRappearsgreen; DEP-1appears red. One representativeexperiment is shown (n =2). Scalebarrepresents 10mm.
(E) HeLa cells expressing DEP-1 (WT or CS) were treated as in (D). The histogram compares the fractions of cells (6SD) displaying vesicular pY1173
in three independent measurements (>100 cells).
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1792Mutagenesis of the invariant catalytic aspartate converts an
active enzyme into a ‘‘substrate trap.’’ This mutant did not alter
localization of EGFR (Figure 4A), and, like WT-DEP-1 and CS,
displayed extensive colocalization with EGFR (Figure 4A).
Notably, both proteins localized almost exclusively to the cell
surface, and their colocalization was most prominent at cell
borders (arrows in Figure 4A).
We next employed a coimmunoprecipitation approach to
examine possible physical interactions between EGFR and
DEP-1. However, immunoprecipitates of both EGFR and
DEP-1 (WT and DA) contained undetectable traces of the other
molecule (data not shown), suggesting that, because of rapid
turnover of many substrate molecules (i.e., EGFRs) by a single
enzyme molecule (i.e., DEP-1), their physical interactions are
very weak and transient. Hence, we adopted an in vitro assay
that employed detergent-solubilized EGFR (from A431 cells)
and a bacterially expressed intracellular domain of DEP-1
fused to glutathione S-transferase (GST-DEP-1). Prior to lysis,
intact A431 cells were incubated with a radiolabeled EGF and
then subjected to covalent crosslinking that enables tagging
EGFR with the radioactive ligand [25]. Unlike the WT form of
GST-DEP-1, the DA mutant robustly interacted with EGFR
(Figure 4B). Two control experiments indicated specific inter-
actions: first, both GST alone and CS displayed no pull-down
activity. Second, pretreatment of cells with vanadate, a PTP
inhibitor that binds to the catalytic site, reproducibly decreased
the signal.
We next asked whether EGFR could transphosphorylate
DEP-1 within the constitutive complex. Unlike CS and WT-
DEP-1, which displayed no tyrosine phosphorylation upon
ectopic expression in HeLa cells, the DA mutant presented
weak phosphorylation on tyrosine residues prior to stimulation
with EGF (Figure 4C). This signal was reproducibly enhanced
following a short (10 min) stimulation with EGF. In line with
direct involvement of EGFR’s kinase activity, a specific inhib-
itor, AG1478, effectively reduced tyrosine phosphorylation of
the DA mutant.
Biophysical Measurements of the Noncovalent
Interactions between EGFR and DEP-1
To further characterize the nature of the interactions between
EGFR and DEP-1, we assayed the efficiency of fluorescence
resonance energy transfer (FRET) between fluorescent deriva-
tives, namely EGFR-mRFP and DEP-1-WT-EGFP (or the
respective DA and CS mutants), using fluorescence lifetime
imaging microscopy (FLIM) as described [26–28]. Because of
suboptimal expression of DEP-1-EGFP and EGFR-mRFP, rela-
tively low FRET efficiencies (w4%) were observed in
cotransfected HeLa cells. Hence, we used MCF7 mammary
cancer cells (Figure 5). The fluorescence lifetime of DEP-1-
WT-EGFP and the DA and CS mutants was remarkably reduced
by coexpression of EGFR-mRFP, which indicates that FRET
occurs between DEP-1-EGFP and EGFR-mRFP (Figures 5A–
5C). However, no significant change in FRET signal was detect-
able upon EGF stimulation in both the WT protein and the CS
mutant. Still, DA demonstrated a significant increase in FRET
signal upon EGF stimulation (Figures 5B and 5D). These data
are consistent with the ability of the DA mutant to bind acti-
vated EGFR (Figure 4B), as well as undergo phosphorylation
on stimulation with EGF (Figure 4C). In conclusion, the bio-
physical measurements suggest that DEP-1 and EGFR
preexist in a physical complex prior to ligand stimulation. On
stimulation, the receptors are better bound by DEP-1 in a rapidFigure 4. DEP-1 and EGFR Colocalize at the Cell Surface, Physically
Interact, and Maintain Bidirectional Enzymatic Interactions
(Aa–Ai) HeLa cells were transiently transfected with vectors encoding HA-
tagged WT DEP-1 (Aa–Ac), a CS mutant (Ad–Af), or a DA mutant (Ag–Ai).
Thereafter, cells were incubated for 32 hr, serum starved for 16 hr, and fixed.
Shown are immunofluorescence images obtained with the indicated anti-
bodies. The merged images (Ac, Af, and Ai) were obtained with the ImageJ
Stack RGB Merge plugin and indicate colocalization (yellow) of EGFR
(green) and DEP-1 (red). Arrows demarcate colocalization at cell borders
and junctions. One representative experiment is shown (n = 3). Scale bar
represents 10 mm.
(B) A431 cells were incubated for 2 hr at 4C with a radiolabeled EGF
(20 ng/ml) and then washed and subjected to covalent crosslinking with
BS3 (1 mM). The crosslinking reaction was subsequently quenched. Cell
lysates were mixed, in the absence or presence of sodium orthovanadate
(0.2 mM), with glutathione beads bound to purified GST, GST-DEP-1 (WT),
DA, or CS mutants and were incubated for 12 hr at 4C. After extensive
washing, the samples were resolved by gel electrophoresis and autoradiog-
raphy (top panel). Staining with Ponceau red (bottom panel) was used to
verify equal gel loading.
(C) HeLa cells were transfected with vectors encoding HA-tagged WT DEP-1
or with the CS or DA mutants. Thereafter, cells were incubated for 32 hr,
serum starved for 16 hr, and then preincubated (as indicated) for 30 min
with a selective EGFR kinase inhibitor (AG1478; 10 mg/ml). This was followed
by EGF stimulation (20 ng/ml; 10 min). DEP-1 was immunoprecipitated (IP)
from whole-cell lysates with anti-HA-agarose beads, followed by immuno-
blotting (IB) with the indicated antibodies.
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Figure 5. FRET Measurements between DEP-1-EGFP and EGFR-mRFP Show Specific Interactions
(A–C) MCF-7 cells were transfected with vectors encoding EGFR-mRFP, along with GFP-tagged WT DEP-1 (A), the DA mutant (B), or the CS mutant (C).
Thereafter, cells were incubated for 32 hr, serum starved for 16 hr, and stimulated with EGF (20 ng/ml; 10 min) prior to fixation and fluorescence measure-
ments. Scale bar represents 20 mm.
(D) The mean FRET efficiency between DEP-1-EGFP and EGFR-mRFP was calculated with the following equation in each pixel and averaged per each cell.
FRET efficiency = 12 tda/tcontrol, where tda is the lifetime displayed by cells coexpressing both DEP-1-EGFP and EGFR-mRFP, and tcontrol is the mean
DEP-1-EGFP lifetime measured in the absence of acceptor. Data are means 6 standard error of the mean (SEM) of 16–23 cells from three independent
experiments. *p < 0.05 for the DA mutant.and reversible manner, because this increase can only be seen
in the presence of a substrate trap (DA) form of DEP-1.
DEP-1 Inhibits EGFR Internalization and Remains at the
Cell Surface after EGFR Is Internalized
Because DEP-1-overexpresing cells displayed virtually no
tyrosine-phosphorylated EGFRs in endosomes (Figure 3D),
we addressed the possibility that the phosphatase inhibits
internalization of active EGFRs. Employing flow cytometry,
we found that following 10 min of stimulation with EGF,
71.9% of surface EGFR molecules translocated from the
surface of siDEP-1-treated cells, as compared to only 47.7%
in siControl cells (Figure 6A). Conversely, 52.6% of surface
receptors internalized in cells transfected with a control
vector, whereas only 30.2% of the receptors underwent inter-
nalization in DEP-1-overexpressing cells (Figure 6B). It is
notable that only a fraction of HeLa cells undergo transfection.Hence, signal magnitude and the consistency of these two
sets of results clearly indicate that DEP-1 decelerates the
rate of ligand-induced EGFR internalization.
Next, we asked whether DEP-1 escorts EGFR to endosomal
compartments. To address this question, HeLa cells were stim-
ulated with fluorescently labeled EGF (Figure 6C). Whereas
fluorescently labeled EGF efficiently translocated into endo-
somes, DEP-1 molecules remained at the cell surface (Fig-
ure 6C), implying molecular segregation. To further address
this scenario, HeLa cells were stimulated with EGF and
surface labeled with antibodies to EGFR or to DEP-1, and both
surface proteins were quantified by flow cytometry (Figure 6D).
As expected, this analysis revealed that 60% of surface-local-
ized EGFR molecules efficiently internalized after 15 min, but
essentially all DEP-1 molecules remained at the cell surface.
As a final test, we asked whether a fraction of DEP-1 reaches
the early endosomal compartment characterized by the
Current Biology Vol 19 No 21
1794presenceof thesmall GTP-bindingprotein RAB5. Asexpected, a
RAB5-GFP fusion protein localized to intracellular vesicles, but
the coexpressed HA-DEP-1 showed little, if any, colocalization
(Figure S3). In conclusion, dephosphorylation by DEP-1 effec-
tively decelerates the rate of EGFR internalization. Eventually,
EGFR molecules are internalized, whereas DEP-1 molecules
remain at the cell surface, perhaps in order to process other
types of RTKs as well as newly delivered EGFR molecules.
DEP-1 Disrupts Physical Association of a Ubiquitin Ligase
Complex with EGFR Molecules and Impairs Its Activation
The distinct fates of EGFR and DEP-1 raised the possibility
that protein ubiquitylation, which underlies endocytic sort-
ing, would differentiate between the two fates. To test this
scenario, we stimulated HeLa cells ectopically expressing
WT-DEP-1 with EGF and tested the ubiquitylation status of
both EGFR and DEP-1. The results confirmed rapid, EGF-
induced ubiquitylation of EGFR (Figure 6E). DEP-1, on the
other hand, displayed relatively weak ubiquitylation, which
was not affected by EGF, in line with different molecular
fates. To test the hypothesis that DEP-1 disrupts receptor
ubiquitylation, we expressed it in HeLa cells briefly stimulated
with EGF and assessed EGFR ubiquitylation. Whereas the WT
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Figure 6. DEP-1 Inhibits EGFR Internalization
and Ubiquitylation and Remains on the Cell
Surface after EGFR Is Internalized
(A) HeLa cells were transfected with the indicated
siRNA oligonucleotides, and 32 hr later they were
serum starved for 16 hr and untreated or treated
with EGF (20 ng/ml; 10 min). Thereafter, surface-
localized EGFR was quantified by flow cytometry.
Numbers represent percents of initial cell surface
EGFR.
(B) HeLa cells transiently expressing HA-DEP-1
or a control vector were assayed as in (A). One
representative experiment (n = 2) is shown.
(C) HeLa cells were stimulated with a fluorescently
labeled EGF (FITC-EGF; 20 ng/ml) for 30 min at
22C and fixed and analyzed by immunofluores-
cence with an antibody to DEP-1.
(D) HeLa cells were serum starved for 16 hr and
stimulated with EGF (20 ng/ml) for the indicated
time intervals. Thereafter, cells were surface
labeled with antibodies to EGFR and DEP-1.
The remaining surface fraction of each protein
was quantified by flow cytometry.
(E) HeLa cells expressing DEP-1-HA were stimu-
lated with EGF (20 ng/ml) for the indicated time
intervals. EGFR and the ectopically expressed
DEP-1 were immunoprecipitated from cell lysates
and subjected to immunoblotting.
(F) HeLa cells were treated as in (E) and stimu-
lated with EGF (20 ng/ml; 5 min). EGFR was
analyzed by immunoblotting, either directly or
following immunoprecipitation. EGFR phosphor-
ylation was detected with an anti-phosphotyro-
sine antibody.
form of DEP-1 caused a decrease in
EGF-induced receptor ubiquitylation,
the CS mutant exerted no marked effect
(Figure 6F). This observation corrobo-
rated the assumption that DEP-1 modu-
lates EGFR trafficking and also raised
the possibility that DEP-1 regulates
interactions of the underlying ubiquitin
ligase, c-CBL, with EGFR [29]. To test this, we examined the
interaction of EGFR with c-CBL, as well as with the CBL’s
adaptor protein, GRB2 [30]. As predicted, ectopic expression
of DEP-1 diminished interactions of EGFR with both c-CBL
and GRB2 (Figure 7A). Because c-CBL’s activation is achieved
via tyrosine phosphorylation, we tested the effect of DEP-1 on
modification of a major site of phosphorylation, namely tyro-
sine 731. Upon DEP-1 overexpression, c-CBL displayed
reduced phosphorylation on this site compared to control
cells (Figure 7B). This result offers a mechanism by which
DEP-1 affects EGFR trafficking: by dephosphorylating EGFR,
and possibly also SRC family kinases involved in phosphoryla-
tion of c-CBL [31, 32], DEP-1 reduces activation of c-CBL
and its recruitment to the activated EGFR, hence inhibiting
subsequent receptor internalization and degradation.
In summary, by dephosphorylating EGFR at the cell surface,
DEP-1 reduces activation and subsequent recruitment of
a dedicated ubiquitin ligase complex (i.e., CBL-GRB2) and
inhibits both receptor ubiquitylation and downstream sig-
naling. Consequently, surface-localized receptors undergo
inactivation, their translocation to endosomes is delayed, and
those receptors that eventually reach the endocytic compart-
ment are largely disarmed (see model in Figure 7C).
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By employing an unbiased screen of all human PTPs, we
identified DEP-1/PTPRJ as a phosphatase acting on EGFR.
Because EGFR drives several types of malignancies in human
(reviewed in [2]) and DEP-1 acts as a suppressor of several
human tumors, including colon, lung, breast [12], and thyroid
[33] cancer, these observations shed new light on the molec-
ular mechanisms enabling DEP-1 to exert tumor-suppressive
activities. Similarly important is the finding that DEP-1 inhibits
both receptor activation at the plasma membrane and transfer
of active receptors to endosomes while it remains confined
to the cell surface (see model in Figure 7C). These findings
explain the previously observed inactivation-reactivation
sequel of EGFR while en route to endosomes [24], and they
also illuminate from a new perspective existing models attrib-
uting signaling capabilities to endosomal EGFRs [34].
RTKs Provide a Potential Mechanistic Basis for Tumor
Suppression by DEP-1
Our screening strategy represents the first exhaustive search
for PTPs specific to EGFR. In support of the reliability of our
strategy, the two enzymes we identified, namely RPTP-kappa
and DEP-1, have respectively been reported as a regulator
Figure 7. DEP-1 Disrupts Physical Association of
a Ubiquitin Ligase Complex with EGFR Mole-
cules and Impairs Its Activation
(A and B) HeLa cells were transfected with control
or DEP-1-HA plasmids, incubated for 32 hr,
serum starved for 16 hr, and stimulated with
EGF (20 ng/ml) for either 5 min (A) or for the indi-
cated time intervals. Whole cell lysates were
immunoblotted with the indicated antibodies.
(C) Model presenting the effect of DEP-1 on
EGFR signaling and endocytosis: a complex
comprising EGFR and DEP-1 preexists at the
surface, especially in highly confluent epithelia.
On EGF binding and receptor phosphorylation
(P), DEP-1 dephosphorylates EGFR, thereby
inhibiting receptor ubiquitylation (Ub) by c-CBL,
which decelerates the rate of receptor internali-
zation and diminishes MAPK signals generated
at the membrane and in endosomes. When
DEP-1 is inactive, as a result of loss of heterozy-
gosity (LOH), for example, EGFR is hyperphos-
phorylated and accordingly relays strong signals
to MAPK, although it gains fast rates of internali-
zation and degradation.
of EGFR in mammalian cells [10] and as
an enzyme whose invertebrate ortholog
genetically interacts with EGFR of
C. elegans [23]. Several other screening
strategies have previously been em-
ployed, including the utilization of
substrate-trapping mutants, which iden-
tified PTP-1B [6] and TC-PTP [7] as EGFR
regulators. The latter enzyme mediates
suppression of EGFR by integrins [9],
suggesting that screening assays per-
formed on distinct extracellular matrices
may identify different enzymes.
Here we demonstrate that DEP-1
suppresses growth signals initiated by
EGFR (Figure 2C). Likewise, previous reports documented an
ability of DEP-1 to suppress signals emanating from other
RTKs, such as PDGF-beta receptors [35], VEGF receptors
[17], and c-Met/HGF receptor [19]. Taken together with our
results, these observations suggest that DEP-1 acts as
a pan-RTK suppressor of growth-factor signals. In combina-
tion with pan-RTK functions, our results attribute suppression
of tumorigenesis to the ability of DEP-1 to dephosphorylate
EGFR and to concurrently inhibit receptor translocation to en-
dosomes and to the nucleus, compartments believed to
support long-term RTK signaling [36]. Supporting lines of
evidence include the ability of an overexpressed DEP-1 to
induce differentiation and suppress tumor cell growth [14,
15]. In the same vein, a transforming acute retrovirus reduces
DEP-1 expression [37], and conversely, forced expression of
DEP-1 suppresses transformation by viral oncogenes [15].
Finally, the gene encoding DEP-1 has been identified as
a candidate for a murine colon cancer susceptibility locus
(SCC1 [12]). Loss of heterozygosity (LOH) of the human gene
is frequently found in colon, breast [38], and thyroid [39] cancer.
Although no previous study associated DEP-1 with a defect
in the transfer of active receptors to endosomes, several pub-
lished findings, such as DEP-1-mediated reduction in MAPK
signaling [40] as well as stabilization of the cell cycle inhibitor
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bition of signals emanating from both the plasma membrane
and intracellular compartments. When combined with the re-
ported ability of DEP-1 to mediate contact inhibition of cell
growth [11], our results suggest the following explanation for
the tumor-suppressive activity of DEP-1: by dephosphorylat-
ing EGFR at the plasma membrane and by halting transfer of
active receptors to intracellular sites of signal generation,
DEP-1 confers contact inhibition of cell growth. Once this
activity of DEP-1 is compromised by LOH or by other mecha-
nisms, epithelial cells are free to fully respond to EGF and to
other growth factors (e.g., HGF and VEGF), thus promoting
cell proliferation, migration, and recruitment of blood vessels
essential for tumor progression.
Functional Implications of the Ability of DEP-1 to Inhibit
Endocytosis of EGFR
By injecting EGF into the portal vein of rats and analyzing
hepatic plasma membrane and endosomal fractions, Bergeron
and colleagues inferred a pre-endocytosis desensitization step
[24]. They later found that the endosomal tyrosine-phosphory-
lated receptors nucleate a signaling complex containing
SHC and the RAS guanine nucleotide exchange factor mSOS
[41]. Similarly, other researchers identified a pool of active,
ligand-bound PDGF-beta receptors in endosomes [42]. These
studies, along with a large series of analyses addressing the
nerve growth factor receptor, led to the realization that the
RTK-harboring endosome serves as a platform for signal
transduction events [34]. In view of the strict compartmentali-
zation of DEP-1 to the plasma membrane and the segrega-
tion from internalizing receptors, the concept of ‘‘signaling en-
dosomes’’ may be revised as follows: while at the plasma
membrane, activation of RTKs like EGFR is tightly controlled
by DEP-1. However, upon translocation to endosomes and
segregation from DEP-1, receptor autophosphorylation is
relieved, which licenses endosomal signaling.
In summary, our study has identified a novel RTK regulatory
pathway: by dephosphorylating EGFR at the plasma mem-
brane and limiting endocytosis of active receptors, DEP-1
tightly controls EGFR’s ability to generate intracellular signals.
This regulatory pathway plays an important role during embry-
onic development of invertebrates [23], and it is manipulated
in human carcinomas, whose DEP-1 frequently undergoes
genetic alterations [12, 38]. Future studies will address the
relevance of the DEP-1 regulatory module to other pairs of
RTKs and the respective receptor-like PTPs.
Experimental Procedures
Reagents and Antibodies
Monoclonal antibodies to EGFR were from Upstate Biotechnology, Alexis
Biotechnology, or were generated in our laboratory. Antibodies to specific
phosphotyrosines of EGFR were from Cell Signaling or Zymed. Other anti-
bodies were from R&D Systems (DEP-1), Babco (ubiquitin), Roche (hemag-
glutinin), Jackson ImmunoResearch Laboratories (Cy2-conjugated), or
Santa Cruz Biotechnology. EGF conjugated to Alexa Fluor 488 streptavidin
was from Molecular Probes.
Cellular Treatments and Transfection
Transient plasmid expression was achieved with the jetPEI transfection
reagent (Polyplus-transfection). siRNA transfection was carried out with Hi-
PerFect Transfection Reagent (QIAGEN). Delivery effectiveness of siRNA
was determined with the KDalert GAPDH Assay Kit (Ambion).Expression Vectors and siRNA Oligonucleotides
Plasmids (pSRa) encoding HA-tagged DEP-1 (wild-type [WT], C1239S [CS],
and D1205A [DA]) have been described [43]. EGFP-tagged DEP-1 was a kind
gift from A. O¨stman. siDEP-1 and control siRNA oligonucleotides were
obtained from Dharmacon (DEP-1; accession number M-008476-01, siCon-
trol; accession number D-001206-14; Table S2). RAB5-GFP was a kind
gift of S. Lev.
Real-Time Quantitative PCR
cDNA was generated using the SuperScript First-Strand Synthesis kit (Invi-
trogen). Real-time PCR analysis was performed using the DyNAmo HS
SYBR Green qPCR Kit (Finnzymes). All experiments were carried out in trip-
licates and normalized to beta-2 microglobulin RNA levels.
Immunoblotting, Immunoprecipitation, and Pull-down Analyses
The procedures and content of buffers were essentially as described [29].
For pull-down, radiolabeled EGF (20 ng/ml) was incubated for 2 hr at 4C
with confluent A431 cells (107 cells). Following extensive washing, saline
containing bis(succinimidyl) suberate (BS3; 1 mM) was incubated with the
cells for 20 min at room temperature. The reagent was quenched in quench-
ing solution (10 mM Tris-HCl [pH 7.5], 200 mM glycine, and 2 mM EDTA).
Cells were harvested in saline and solubilized in the absence or presence
of 0.2 mM sodium orthovanadate. Subsequently, glutathione beads bound
to different GST proteins (0.05 mg each) were added, and the mixtures were
rotated for 12 hr at 4C prior to washing and gel electrophoresis.
Immunofluorescence
Cells were treated as described [44]. Images of fixed cells were recorded with
a DeltaVision system (Applied Precision) that included an Olympus IX71 in-
verted fluorescence microscope equipped with a charge-coupled camera
(Photometrics), a 100 W mercury lamp, and excitation and emission filter
wheels. Images were acquired with an Olympus Plan ApoN 603 1.42 NA
objective. pY1173 fluorescence intensity of EGFR-positive vesicles was
determined by calculating the mean gray value within the selected vesicular
areas. Fluorescence intensity was measured using a VICTOR2 Multilabel
Counter (PerkinElmer).
Cell Proliferation Assay
Cells grown in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum were transfected with siRNA nucleotides (25 nM)
obtained from Applied Biosystems (DEP-1; catalog # S230208 and scram-
bled; catalog #AM4611). After 48 hr, cells were replated in 96-well plates,
and, following an overnight incubation, media were changed to 1% serum;
relative cell proliferation was measured on day 0 and day 3 using the WST-1
Kit from Chemicon.
Flow Cytometry
Flow cytometry was carried out as described [45].
FRET Determination by Multiphoton FLIM Measurements
FLIM was performed with a custom-built multiphoton system constructed
around an upright 90i fluorescence microscope (Nikon) and similar to that
described elsewhere [46].
Supplemental Data
Supplemental Data include three figures and two tables and can be
found online at http://www.cell.com/current-biology/supplemental/S0960-
9822(09)01761-8.
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